NEW DATA PRESENTED AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE 2025 CONFIRMS PHARMACOLOGICAL EFFECT OF LEQEMBI® (LECANEMAB-IRMB) ON NEUROTOXIC AΒ PROTOFIBRILS IN CSF

Reuters · 3d ago

Please log in to view news